We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.

Transforming cutting-edge research into companies to solve the world’s greatest challenges and deliver strong returns for investors.
Powered by a unique partnership with the University of Oxford, we work with leading scientific minds and global investors to build transformational ventures.

Johannes Feldmann and Vaysh Kewada, Salience

Our team works hand in hand with world-class researchers and entrepreneurs. We find bold ideas, fund them with patient capital, and build companies ready to change the world.
Dr Chris Ballance, Oxford Ionics
Dr Chris Ballance, Oxford Ionics

Ten years in, we’ve built a proven venture-building engine and a diverse pipeline with multi-billion-pound potential.

With more than 60 people based in the heart of Oxford, we are united by one goal: turning world-class science into world-changing, billion-pound companies.

From academic breakthrough to $1bn acquisition – a story of deep science, patient capital, and bold ambition.

Alethio Therapeutics is redefining how we treat incurable blood cancers – by targeting the cells that drive them.
Oxford researchers & innovators
We partner with researchers and innovators across Oxford, Harwell and Culham to explore commercial potential, co-create ventures and build companies.
Investors
We’ve raised over £850m from global investors keen to access Oxford’s diverse, world-leading science. Our shareholders don’t just back OSE – many also co-invest alongside us.
Co-investors
We partner with specialist global investors to fund and scale our companies – from pre-seed to growth. Together, OSE and our co-investors have invested more than £3bn.
46 Woodstock Road,
Oxford, OX2 6HT